Loading
What changed between revision 1 and revision 2, compared over the article's markdown source with its frontmatter — so a change to status, evidence or reversibility shows up as the edit it is.
Older · revision 1
Import· initial corpus import, not an edit
Initial import of content/glp-1-receptor-agonists.md — the filesystem corpus, unchanged. Not an edit.
18.1 kB
Revision 1
Revision 2
lines 8–14 → 8–147 unchanged lines not shown
categories: ["longevity", "society"]categories: ["longevity", "society"]tags: ["obesity", "incretins", "diabetes", "clinical trials", "metabolic health", "drug access"]tags: ["obesity", "incretins", "diabetes", "clinical trials", "metabolic health", "drug access"]summary: "Drugs that mimic the gut hormone GLP-1 to lower blood glucose and food intake, producing large weight loss that persists only while treatment continues."summary: "Drugs that mimic the gut hormone GLP-1 to lower blood glucose and food intake, producing large weight loss that persists only while treatment continues."updated: "2026-07-27"updated: "2026-10-29"humanEvidence: "Randomized trials in tens of thousands of adults show sustained weight loss and fewer cardiovascular events in people with overweight or obesity and established heart disease; no human trial has tested lifespan."humanEvidence: "Randomized trials in tens of thousands of adults show sustained weight loss and fewer cardiovascular events in people with overweight or obesity and established heart disease; no human trial has tested lifespan."access: "Approved and widely prescribed in most high-income countries for diabetes and weight management; US list prices remain on the order of a thousand dollars a month and payer coverage is heavily restricted."access: "Approved and widely prescribed in most high-income countries for diabetes and weight management; US list prices remain on the order of a thousand dollars a month and payer coverage is heavily restricted."reversibility: "reversible"reversibility: "reversible"lines 48–72 → 48–7233 unchanged lines not shown
## How they work## How they work GLP-1 is secreted by enteroendocrine cells lining the distal small intestine and colon when nutrientsGLP-1 is secreted by enteroendocrine cells lining the distal small intestine and colon whenarrive. It amplifies insulin release in a glucose-dependent way, which is why these drugs rarelynutrients arrive. It amplifies insulin release in a glucose-dependent way, which is why these drugscause hypoglycaemia on their own; it suppresses glucagon; it slows gastric emptying; and it bindsrarely cause hypoglycaemia on their own; it suppresses glucagon; it slows gastric emptying; and itreceptors in the hypothalamus and the area postrema, where the signal registers asbinds receptors in the hypothalamus and the area postrema, where the signal registers assatiety.[^drucker2018] The native peptide is destroyed within a few minutes by the enzyme DPP-4, sosatiety.[^drucker2018] The native peptide is destroyed within a few minutes by the enzyme DPP-4, sothe therapeutic problem was never finding the hormone but making it last.the problem for drug developers was how to make the hormone last. Two solutions dominate. The first came from a lizard: exendin-4, isolated from Gila monster venom, isTwo solutions have prevailed. The first came from a lizard: exendin-4, isolated from Gila monsternaturally resistant to DPP-4 and activates the human receptor, and became exenatide.[^eng1992] Thevenom, is naturally resistant to DPP-4 and activates the human receptor, and becamesecond is chemical modification of the human sequence, combining amino-acid substitutions with aexenatide.[^eng1992] The second is chemical modification of the human sequence, combining amino-acidfatty-acid chain that binds circulating albumin and slows both enzymatic degradation and renalsubstitutions with a fatty-acid chain that binds circulating albumin and slows both enzymaticclearance. That combination makes liraglutide a once-daily injection and semaglutide a once-weeklydegradation and renal clearance. That combination makes liraglutide a once-daily injection andone.semaglutide a once-weekly one. Most of the weight loss follows from eating less. That resemblance to a caloric deficit is what firstMost of the weight loss follows from eating less. That resemblance to a caloric deficit is what firstdrew attention from biogerontology, though the analogy to [[caloric-restriction]] is loose: dietarydrew attention from biogerontology, though the analogy to [[caloric-restriction]] is loose: dietaryrestriction experiments hold lean animals below their normal intake, while these drugs mainly removerestriction experiments hold lean animals below their normal intake, while these drugs mainly removeexcess adiposity from people who have it. Whether any of the cardiovascular or renal benefit isexcess adiposity from people who have it. Whether any of the cardiovascular or renal benefit isindependent of weight loss is actively researched and unsettled.independent of weight loss is unsettled and under active research. > [!note] Terminology> [!note] Terminology> GLP-1 and GIP are the two incretin hormones. Semaglutide, made by Novo Nordisk and sold as Ozempic> GLP-1 and GIP are the two incretin hormones. Semaglutide, made by Novo Nordisk and sold as Ozempiclines 97–106 → 97–10624 unchanged lines not shown
The weight results exceed those of any previously approved weight-loss drug. In STEP 1, adults withThe weight results exceed those of any previously approved weight-loss drug. In STEP 1, adults withoverweight or obesity and without diabetes lost roughly 15 percent of body weight on average over 68overweight or obesity and without diabetes lost roughly 15 percent of body weight on average over 68weeks on semaglutide, against about 2 percent on placebo.[^wilding2021] Tirzepatide, at its highest dose inweeks on semaglutide, against about 2 percent on placebo.[^wilding2021] Tirzepatide, at its highestSURMOUNT-1, averaged around a fifth.[^jastreboff2022] Means conceal a wide spread: a substantialdose in SURMOUNT-1, averaged around a fifth.[^jastreboff2022] Means conceal a wide spread: aminority lose very little, and both trials gave every participant diet and activity counsellingsubstantial minority lose very little, and both trials gave every participant diet and activityalongside the injection.counselling alongside the injection. The strongest hard-outcome evidence is the SELECT cardiovascular outcomes trial, which enrolledThe strongest hard-outcome evidence is the SELECT cardiovascular outcomes trial, which enrolledadults with overweight or obesity and established cardiovascular disease but without diabetes, andadults with overweight or obesity and established cardiovascular disease but without diabetes, andlines 115–121 → 115–1218 unchanged lines not shown
type 2 diabetes and chronic kidney disease.[^perkovic2024] Trials have reported improved symptoms intype 2 diabetes and chronic kidney disease.[^perkovic2024] Trials have reported improved symptoms inheart failure with preserved ejection fraction, reduced severity ofheart failure with preserved ejection fraction, reduced severity of[[sleep-and-longevity|obstructive sleep apnoea]] with tirzepatide, and reduced knee osteoarthritis[[sleep-and-longevity|obstructive sleep apnoea]] with tirzepatide, and reduced knee osteoarthritispain. The failures matter as much: Novo Nordisk reportedpain. The failures are as informative: Novo Nordisk reportedin late 2025 that two large trials of oral semaglutide in early Alzheimer's disease did not slowin late 2025 that two large trials of oral semaglutide in early Alzheimer's disease did not slowprogression of the disease, the most direct test so far of the claim that incretin drugs act broadlyprogression of the disease, the most direct test so far of the claim that incretin drugs act broadlyon age-related disease rather than through metabolism.[^novo2025]on age-related disease rather than through metabolism.[^novo2025]lines 133–139 → 133–13911 unchanged lines not shown
age-related conditions is the shape of result the [[geroscience-hypothesis]] predicts, and the shapeage-related conditions is the shape of result the [[geroscience-hypothesis]] predicts, and the shape[[metformin|the TAME trial]] was designed to produce.[[metformin|the TAME trial]] was designed to produce. The case against is that this is disease treatment doing what disease treatment does. RestoringThe case against is that the drugs are doing what any effective disease treatment does. Restoringsomeone with obesity toward the metabolic state of someone who never had it returns them to asomeone with obesity toward the metabolic state of someone who never had it returns them to abaseline; it does not push past it. Nothing in the record shows a change in the underlying rate ofbaseline; it does not push past it. Nothing in the record shows a change in the underlying rate ofaging, and the animal work, overwhelmingly in rodents, has measured metabolic and body-weightaging, and the animal work, overwhelmingly in rodents, has measured metabolic and body-weightlines 165–171 → 165–17125 unchanged lines not shown
produces by any route, but it is a sharper concern here because the drugs are increasingly used byproduces by any route, but it is a sharper concern here because the drugs are increasingly used byolder adults in whom muscle loss is itself a driver of frailty. Trials pairing incretin drugs witholder adults in whom muscle loss is itself a driver of frailty. Trials pairing incretin drugs withantibodies against the activin and [[myostatin-inhibition|myostatin]] pathways are underway, andantibodies against the activin and [[myostatin-inhibition|myostatin]] pathways are underway, andresistance training is the countermeasure with the longest evidence base — one more place whereresistance training is the countermeasure with the longest evidence base. Here, as elsewhere,[[exercise-and-aging|the exercise literature]] is the comparator any drug has to beat.[[exercise-and-aging|the exercise literature]] is the comparator any drug has to beat. ## Risks## Riskslines 182–189 → 182–18910 unchanged lines not shown
> Long-term dosing produced thyroid C-cell tumours in rats and mice, which is the basis for a boxed> Long-term dosing produced thyroid C-cell tumours in rats and mice, which is the basis for a boxed> warning and a contraindication in people with a personal or family history of medullary thyroid> warning and a contraindication in people with a personal or family history of medullary thyroid> carcinoma. Rodent C-cells express the GLP-1 receptor far more abundantly than human ones do, and> carcinoma. Rodent C-cells express the GLP-1 receptor far more abundantly than human ones do, and> no corresponding human effect has been demonstrated. The warning stands because the question is> no corresponding human effect has been demonstrated. The warning reflects an open question; the> open, not because the finding has been shown to transfer.> finding has not been shown to transfer to humans. ## Access and cost## Access and cost lines 197–205 → 197–2057 unchanged lines not shown
a price collapse.a price collapse. Obesity prevalence is rising fastest in middle-income countries, where these drugs are furthest outObesity prevalence is rising fastest in middle-income countries, where these drugs are furthest outof reach, making this a clean current example of the pattern described underof reach, making this a clear current example of the pattern described under[[access-and-inequality]]: an effective intervention distributed inversely to need. Cosmetic use by[[access-and-inequality]]: an effective intervention distributed inversely to need. Cosmetic use bypeople at or near typical weight raises the treatment–enhancement boundary thatpeople at or near typical weight raises the treatment-enhancement boundary that[[bioethics-of-enhancement|enhancement ethics]] has argued over for decades, with the added feature[[bioethics-of-enhancement|enhancement ethics]] has argued over for decades, with the added featurethat supply diverted to it is supply unavailable to someone with diabetes. The drugs also anchor athat supply diverted to it is supply unavailable to someone with diabetes. The drugs also anchor aconsumer metabolic-monitoring market, [[continuous-glucose-monitoring]] andconsumer metabolic-monitoring market, [[continuous-glucose-monitoring]] andlines 221–227 → 221–22715 unchanged lines not shown
establish and correspondingly easy to assert. The stronger and more testable claim is narrower: thatestablish and correspondingly easy to assert. The stronger and more testable claim is narrower: thatthey compress the years of illness at the end of a life without moving its end, which isthey compress the years of illness at the end of a life without moving its end, which is[[compression-of-morbidity]] rather than any change in [[maximum-human-lifespan]]. That is a large[[compression-of-morbidity]] rather than any change in [[maximum-human-lifespan]]. That is a largeachievement, and it is not the one the popular framing has settled on.achievement, but not the one the popular framing has settled on. ## See also## See also removed, struck through added, underlinedLine numbers count the serialised markdown of each revision, frontmatter included.
222 lines are the same in both revisions, and 160 of them are not shown. Neither revision here is necessarily the current article — read GLP-1 receptor agonists for the text this wiki stands behind today.